Chemistry: analytical and immunological testing – For preexisting immune complex or auto-immune disease
Reexamination Certificate
2011-02-10
2011-11-22
Stoica, Elly-Gerald (Department: 1647)
Chemistry: analytical and immunological testing
For preexisting immune complex or auto-immune disease
C530S350000, C424S130100, C424S140100
Reexamination Certificate
active
08062907
ABSTRACT:
Disclosed is a method for assessing a severity of rheumatoid arthritis. The method involves measuring in a patient sample a concentration of anti-cyclic citrullinated peptides (anti-CCP) and serum amyloid A, combining the concentrations determined to obtain a combined value, and comparing the combined value to a cut-off value established from a reference population. In another method, a marker selected from the group consisting of C-reactive protein (CRP), interleukin 6 (IL-6), S100 protein, osteopontin, rheumatoid factor (RF), matrix metalloprotease 1 (MMP-1), matrix metalloprotease 3 (MMP-3), hyaluronic acid, and soluble CD14 (sCD14) may also be determined along with the anti-CCP and serum amyloid A.
REFERENCES:
patent: 1213586 (2002-06-01), None
patent: 1431310 (2004-06-01), None
patent: 98/08946 (1998-03-01), None
patent: 98/22503 (1998-05-01), None
patent: 99/28344 (1999-06-01), None
patent: 99/35167 (1999-07-01), None
patent: 01/46222 (2001-06-01), None
patent: 03/050542 (2003-06-01), None
Kumon et al., Rheumatoid arthritis exhibits reduced acute phase and enhanced constitutive serum amyloid A protein in synovial fluid relative to serum. A comparison with C- reactive protein. J. Rheumatol. 24, 14-19, 1997.
Suzuki et al., High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis, Scand. J. Rheumatol. 32, 197-204, 2003.
Al-Dehaimi, A. et al., Serum Galactosyl Hydroxylysine as a Biochemical Marker of Bone Resorption, Clinical Chemistry, 1999, pp. 676-681, vol. 45, No. 5.
Arnett, F. et al., The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis, Arthritis and Rheumatism, Mar. 1988, pp. 315-324, vol. 31, No. 3.
Ballara, S. et al., Raised Serum Vascular Endothelial Growth Factor Levels are Associated with Destructive Change in Inflammatory Arthritis, Arthritis and Rheumatism, Sep. 2001, pp. 2055-2064, vol. 44, No. 9.
Bartfield, H., Distribution of Rheumatoid Factor Activity in Nonrheumatoid States, Annals of the New York Academy of Sciences, 1969, pp. 30-40, vol. 168.
Bas, S. et al., Comparative Study of Different Enzyme Immunoassays for Measurement of IgM and IgA Rheumatoid Factors, Annuals of the Rheumatic Diseases, 2002, pp. 505-510, vol. 61.
Billinghurst, R. et al., Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage, The Journal of Clinical Investigation, Apr. 1997, pp. 1534-1545, vol. 99, No. 7.
Bonde, M., et al., Immunoassay for Quantifying Type I Collagen Degradation Products in Urine Evaluated, Clinical Chemistry, 1994, pp. 2022-2025, vol. 40, No. 11.
Brenchley, P. et al., Angiogenesis in inflammatory joint disease: a target for therapeutic intervention, Clinical and Experimental Immunology, 2000, pp. 426-429, vol. 121.
Burmeister, G. et al., A selective method for determining MRP8 and MRP14 homocomplexes and heterocomplexes by sandwich ELISA for the discrimination of active and non-active osteoarthritis from rheumatoid arthritis in sera and synovial fluids, Inflammopharmacology, 1995, pp. 221-230, vol. 3.
Chabas, D. et al., The influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease, Science, Nov. 23, 2001, pp. 1731-1735, vol. 294.
Chambers, R. et al., Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity, Annals of the Rheumatoid Arthritis Diseases, 1983, pp. 665-667, vol. 42.
Cunnane, G. et al., Serum Amyloid A in the Assessment of Early Inflammatory Arthritis, The Journal of Rheumatology, 2000, pp. 58-63, vol. 27, No. 1.
Cunnane, G., Amyloid precursors and amyloidosis in inflammatory arthritis, Current Opinion in Rheumatology, 2001, pp. 67-73, vol. 13.
Feng, Y. et al., Parallel Detection of Autoantibodies with Microarrays in Rheumatoid Diseases, Clinical Chemistry, 2004, pp. 416-422, vol. 50, No. 2.
Foell, D. et al., Expression of the pro-inflammatory protein S100Al2 (EN-RAGE) in rheumatoid and psoriatic arthritis, Rheumatology, 2003, pp. 1383-1389, vol. 42.
Friedman, J., Regularized Discriminant Analysis, Journal of the American Statistical Association, Mar. 1989, pp. 165-175, vol. 84, No. 405.
Gineyts, E. et al., Urinary excretion of glucosyl-galactosyl pyradinoline: a specific biochemical marker of synovium degradation, Rheumatology, 2001, pp. 351-323, vol. 40.
Gundberg, C., Biology, Physiology, and Clinical Chemistry of Osteocalcin, Journal of Clinical Ligand Assay, Summer 1998, pp. 128-138, vol. 21, No. 2.
Hamakawa, H. et al., Clnical significance of MMP-3 in patients with rheumatoid arthritis: comparison with other inflammatory markers (IL-6, IL-8), Rinsho Byori, 2003, pp. 13-18, vol. 51, Abstract.
Hastie, T. et al., The Elements of Statistical Learning, Spring Series in Statistics, 2001.
Hochberg, M. et al., The American College of Rhematology 1991 Revised Criteria for the Classification of Rheumatoid Arthritis, Arthritis and Rheumatism, May 1992, pp. 498-502, vol. 35, No. 5.
Horneff, G. et al., Reduction of monocyte-macrophase activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis, Clinical and Experimental Immunology, 1993, pp. 207-213, vol. 91.
Ishiguro, N. et al., Relationships of Matrix Metalloproteinases and their Inhibitors to Cartilae Proteoglycan and Collagen Turnover and Inflammation as Revealed by Analyses of Synovial Fluids From Patients with Rheumatoid Arthritis, Arthritis and Rheumatism, Nov. 2001, pp. 2503-2511, vol. 44, No. 11.
Johansen, C. et al., IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications, Clinical and Experimental Rheumatology, 1996, pp. 301-304, vol. 14.
Johansen, J. et al., Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction, Scandinavian Journal of Rheumatology, 2001, pp. 297-304, vol. 30.
Kaufmann, J. et al., Hydroxypyridinium collagen crosslinks in serum, urine, synovial fluid and synovial tissue in patients with rheumatoid arthritis compared with osteoarthritis, Rheumatology 2003, pp. 314-320, vol. 42.
Kellgren, J. et al., Radiological Assessment of Osteo-Arthrosis, Annals of the Rheumatic Diseases, 1957, pp. 494-502, vol. 16.
Knott, L. et al., Collagen Cross-Links in Mineralizing Tissues: A Review of Their Chemistry, Function, and Clinical Relevance, Bone, Mar. 1998, pp. 181-187, vol. 22, No. 3.
Kumon et al., Rheumatoid arthritis exhibits reduced acute phase and enhanced constitutive serum amyloid A protein in synovial fluid relative to serum. A comparison with C-reactive protein, Journal of Rheumatology, 1997, pp. 14-19, vol. 24 (abstract only).
Lee, D. et al Clinical Utility of the Anti-CCP Assay in Patients with Rheumatic Diseases, Annals of the Rheumatic . Diseases, 2003, pp. 870-874, vol. 62.
Lee, S. et al., Vascular Endothelial Growth Factor Levels in the Serum and Synovial Fluid of Patients with Rheumatoid Arthritis, Clinical and Experimental Rheumatology, 2001, pp. 321-324, vol. 19.
Lorenzo, P. et al., A Novel Cartilage Protein (CILP) Present in the Mid-zone of Human Articular Cartilage Increases with Age, The Journal of Biological Chemistry, Sep. 4, 1998, pp. 23463-23468, vol. 273, No. 36.
Marcellitti, J. et al., Assessment of serological markers associated with rheumatoid arthritis. Diagnostic autoantibodies and convention disease activity markers, Clinical and Applied Immunology Reviews, 2003, pp. 109-123, vol. 4.
McLachlan, G., Discriminant Analysis and Statistical Pattern Recognition, Wiley Series in Probability and Mathematical Statistics, 1992.
Migita, K. K et al., Serum Amyloid A Protein Induces Production of Matrix Metalloproteinases by Human Synovial Fibroblasts, Laboratory Investigation, May 1998, pp. 535-539, vol. 78.
Moore, T. et al., Rheumatoid Factors, Clinical Biochemistry, 1993, pp. 75-84, vol. 26.
Mozes, G. et al., Serum Amyloid A: An Extremely Sensitive marker for Intensity of Tissue Damage in Trauma Patients and Indicator of Acute Response in Various Diseases, The Journal of Trauma, p. 7174, vol. 29, No. 1.
M
Grunert Veit Peter
Karl Johann
Wild Norbert
Zolg Werner
Roche Diagnostics Operations Inc.
Stoica Elly-Gerald
LandOfFree
Method to assess the severity of rheumatoid arthritis by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to assess the severity of rheumatoid arthritis by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to assess the severity of rheumatoid arthritis by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4304629